bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
192 hedge funds and large institutions have $3.12B invested in bluebird bio in 2015 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 93 increasing their positions, 59 reducing their positions, and 63 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 59
7% less call options, than puts
Call options by funds: $59.5M | Put options by funds: $64M
18% less funds holding
Funds holding: 235 → 192 (-43)
47% less capital invested
Capital invested by funds: $5.86B → $3.12B (-$2.74B)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
67% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$153M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$86.7M |
| 3 |
O
OppenheimerFunds
New York
|
+$61.8M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$46.4M |
| 5 |
O
OrbiMed
New York
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$57.1M |
| 2 |
TCP
Tourbillon Capital Partners
New York
|
-$42.1M |
| 3 |
PC
Passport Capital
San Francisco,
California
|
-$36.2M |
| 4 |
Two Sigma Investments
New York
|
-$32.6M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$25M |
BLUE Hedge Fund Activity: Q3 2015 in Review
192 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2015, worth a combined $3.12B — down 47% from $5.86B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of BLUE and 21 opened new positions — a net loss of 42 holders — while 59 trimmed existing stakes and 93 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $153M. The largest seller was Lord, Abbett & Co, cutting an estimated $57.1M.
- 192 institutional investors held bluebird bio (BLUE) as of Q3 2015, down from 235 in Q2 2015.
- Funds reported $3.12B of bluebird bio stock for Q3 2015, down 47% quarter-over-quarter.
- 21 funds opened new bluebird bio positions in Q3 2015 and 63 closed out, a net change of -42 holders.
- The largest bluebird bio buyer in Q3 2015 was Baillie Gifford & Co, an estimated $153M added.
- The largest bluebird bio seller in Q3 2015 was Lord, Abbett & Co, an estimated $57.1M sold.
Based on aggregated 13F filings for Q3 2015.